Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
ARWR Analyst Ratings
Moderate Buy
7 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ARWR Stock 12 Month Forecast
Average Price Target
$39.33
▲(152.76%Upside)
| Highest Price Target$80.00 | Average Price Target$39.33 | Lowest Price Target$17.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$15.5
Hold
-0.39%
Downside
Reiterated
05/14/25
Arrowhead Pharmaceuticals' overall stock score reflects its significant financial challenges, including negative profitability and cash flow issues. Despite these hurdles, the stock has potential upside due to positive earnings call sentiment, strategic partnerships, and upcoming product launches. Technical indicators show mixed signals, while the appointment of a new CFO adds a positive note to its corporate strategy.
Bernstein
―
Hold
―
Assigned
05/27/25
H.C. Wainwright
$80
Buy
414.14%
Upside
Reiterated
05/20/25
UBS
$71→$63
Buy
304.88%
Upside
Reiterated
05/14/25
B.Riley Financial
$38
Buy
144.22%
Upside
Initiated
05/14/25
Cantor Fitzgerald
―
Buy
―
Reiterated
05/13/25
TD Cowen
―
Buy
―
Reiterated
05/13/25
Morgan Stanley
$29
Hold
86.38%
Upside
Reiterated
05/13/25
RBC Capital
$40
Buy
157.07%
Upside
Reiterated
05/13/25
Bank of America Securities
$41→$39
Buy
150.64%
Upside
Reiterated
05/12/25
Citi
$17
Hold
9.25%
Upside
Reiterated
05/12/25
Leerink Partners
$22
Hold
41.39%
Upside
Reiterated
05/12/25
Goldman Sachs
$26
Hold
67.10%
Upside
Reiterated
03/10/25
Piper Sandler
$45
Buy
189.20%
Upside
Reiterated
02/26/25
Chardan Capital
$60
Buy
285.60%
Upside
Reiterated
02/11/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$15.5
Hold
-0.39%
Downside
Reiterated
05/14/25
Arrowhead Pharmaceuticals' overall stock score reflects its significant financial challenges, including negative profitability and cash flow issues. Despite these hurdles, the stock has potential upside due to positive earnings call sentiment, strategic partnerships, and upcoming product launches. Technical indicators show mixed signals, while the appointment of a new CFO adds a positive note to its corporate strategy.
Bernstein
―
Hold
―
Assigned
05/27/25
H.C. Wainwright
$80
Buy
414.14%
Upside
Reiterated
05/20/25
UBS
$71→$63
Buy
304.88%
Upside
Reiterated
05/14/25
B.Riley Financial
$38
Buy
144.22%
Upside
Initiated
05/14/25
Cantor Fitzgerald
―
Buy
―
Reiterated
05/13/25
TD Cowen
―
Buy
―
Reiterated
05/13/25
Morgan Stanley
$29
Hold
86.38%
Upside
Reiterated
05/13/25
RBC Capital
$40
Buy
157.07%
Upside
Reiterated
05/13/25
Bank of America Securities
$41→$39
Buy
150.64%
Upside
Reiterated
05/12/25
Citi
$17
Hold
9.25%
Upside
Reiterated
05/12/25
Leerink Partners
$22
Hold
41.39%
Upside
Reiterated
05/12/25
Goldman Sachs
$26
Hold
67.10%
Upside
Reiterated
03/10/25
Piper Sandler
$45
Buy
189.20%
Upside
Reiterated
02/26/25
Chardan Capital
$60
Buy
285.60%
Upside
Reiterated
02/11/25
Best Analysts Covering Arrowhead Pharmaceuticals
1 Month
xxx
Success Rate
13/24 ratings generated profit
Average Return
-1.68%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.17% of your transactions generating a profit, with an average return of -1.68% per trade.
3 Months
xxx
Success Rate
21/40 ratings generated profit
Average Return
+7.21%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.50% of your transactions generating a profit, with an average return of +7.21% per trade.
1 Year
Success Rate
19/40 ratings generated profit
Average Return
+27.60%
reiterated a buy rating 4 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 47.50% of your transactions generating a profit, with an average return of +27.60% per trade.
2 Years
xxx
Success Rate
13/40 ratings generated profit
Average Return
+44.72%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 32.50% of your transactions generating a profit, with an average return of +44.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ARWR Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
May 25
Strong Buy
12
15
17
13
13
Buy
3
2
1
1
3
Hold
9
7
4
5
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
24
24
22
19
25
Each month's total comprises the sum of three months' worth of ratings.
ARWR Financial Forecast
ARWR Stock Forecast FAQ
What is ARWR’s average 12-month price target, according to analysts?
Based on analyst ratings, Arrowhead Pharmaceuticals’s 12-month average price target is 39.33.
What is ARWR’s upside potential, based on the analysts’ average price target?
Arrowhead Pharmaceuticals has 152.76% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ARWR a Buy, Sell or Hold?
Arrowhead Pharmaceuticals has a consensus rating of Moderate Buy which is based on 7 buy ratings, 5 hold ratings and 0 sell ratings.
What is Arrowhead Pharmaceuticals’s price target?
The average price target for Arrowhead Pharmaceuticals is 39.33. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $17.00. The average price target represents 152.76% Increase from the current price of $15.56.
The highest analyst price target is $80.00 ,the lowest forecast is $17.00. The average price target represents 152.76% Increase from the current price of $15.56.
What do analysts say about Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of ARWR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.